TOKYO, Nov 30, 2022 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. and Biogen Inc. announced today that the results from Eisai’s large global …
Eisai to Present Full Findings from Lecanemab Confirmatory Phase 3 Clinical Trial (Clarity AD) and Other Alzheimer’s Disease Research at The 15th Clinical Trials on Alzheimer’s Disease (CTAD) Conference
TOKYO, Nov 21, 2022 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. will present the efficacy, safety and biomarker findings from the company’s Phase …
Eisai’s Lecanemab Confirmatory Phase 3 Clarity AD Study Met Primary Endpoint
TOKYO, Sep 28, 2022 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) announced positive topline results from Eisai’s large …